Top MarketRank™ StocksTop MarketRank™Top-Rated Dividend StocksTop-Rated DividendNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $32.75 -0.26 (-0.79%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$32.72 -0.03 (-0.09%) As of 03/10/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Royalty Pharma Stock (NASDAQ:RPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Royalty Pharma alerts:Sign Up Key Stats Today's Range$32.53▼$33.1950-Day Range$25.51▼$33.8652-Week Range$24.05▼$34.20Volume5.29 million shsAverage Volume2.82 million shsMarket Capitalization$18.88 billionP/E Ratio22.59Dividend Yield2.69%Price Target$41.60Consensus RatingBuy Company OverviewRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More… Remove Ads Royalty Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks99th Percentile Overall ScoreRPRX MarketRank™: Royalty Pharma scored higher than 99% of companies evaluated by MarketBeat, and ranked 18th out of 930 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.24% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 8.24% in the coming year, from $4.49 to $4.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 22.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 22.59, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 23.97.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 2.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.11% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 5.15%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.64%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 60.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 18.11% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Sustainability and ESG3.7 / 5Environmental Score-2.25 Percentage of Shares Shorted4.11% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 5.15%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.27 News SentimentRoyalty Pharma has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Royalty Pharma this week, compared to 7 articles on an average week.Search Interest20 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Stock News HeadlinesArgos Therapeutics (OTCMKTS:ARGSQ) vs. Royalty Pharma (NASDAQ:RPRX) Critical AnalysisMarch 7, 2025 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Receives $41.60 Consensus Price Target from BrokeragesMarch 6, 2025 | americanbankingnews.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.March 11, 2025 | Stansberry Research (Ad)1 Stock Under $50 with Exciting Potential and 2 to IgnoreMarch 4, 2025 | finance.yahoo.comRoyalty Pharma to Present at TD Cowen’s 45th Annual Health Care ConferenceFebruary 27, 2025 | markets.businessinsider.comRoyalty Pharma to Present at TD Cowen's 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comWhy Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025February 23, 2025 | msn.com2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall StreetFebruary 19, 2025 | msn.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $25.51 at the beginning of the year. Since then, RPRX shares have increased by 28.4% and is now trading at $32.75. View the best growth stocks for 2025 here. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) issued its quarterly earnings data on Tuesday, February, 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a trailing twelve-month return on equity of 24.40% and a net margin of 37.94%. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional investors of Royalty Pharma include Vanguard Group Inc. (6.34%), FMR LLC (4.48%), Adage Capital Partners GP L.L.C. (2.88%) and Baillie Gifford & Co. (2.40%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist and Rory B Riggs. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Bristol-Myers Squibb (BMY), Chevron (CVX), McKesson (MCK), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW) and Invesco QQQ (QQQ). Company Calendar Ex-Dividend for 12/10 Dividend11/15/2024Dividend Payable12/10/2024Last Earnings2/11/2025Ex-Dividend for 3/10 Dividend2/21/2025Today3/10/2025Dividend Payable3/10/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Stock Price Target$41.60 High Stock Price Target$51.00 Low Stock Price Target$28.00 Potential Upside/Downside+27.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$1.45 Trailing P/E Ratio22.59 Forward P/E Ratio7.29 P/E Growth2.31Net Income$858.98 million Net Margins37.94% Pretax Margin58.79% Return on Equity24.40% Return on Assets14.01% Debt Debt-to-Equity Ratio0.64 Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$2.26 billion Price / Sales8.34 Cash Flow$4.12 per share Price / Cash Flow7.94 Book Value$17.94 per share Price / Book1.83Miscellaneous Outstanding Shares576,453,000Free Float477,827,000Market Cap$18.88 billion OptionableOptionable Beta0.47 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RPRX) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.